No Data
No Data
Dizhe Pharmaceutical (688192): Revenue is in line with expectations, core products are progressing in an orderly manner worldwide
The 2023 and 1Q24 results are in line with our expectations. The company announced the 2023 and 1Q24 results: 2023 revenue of 91.289 million yuan, net profit to mother of 1.11 billion yuan, in line with our expectations. incorporation
These 4 Measures Indicate That Dizal (Jiangsu) Pharmaceutical (SHSE:688192) Is Using Debt Reasonably Well
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of permanent loss is the risk I worry about... and every practical investor I know wor
Express News | Dizhe Pharmaceutical: Schwarzhe's performance exceeded expectations and accelerated commercialization
Dizhe Pharmaceutical (688192.SH) announced its 2023 annual results with a net loss of 1.08 billion yuan
Dizhe Pharmaceutical (688192.SH) released its 2023 annual performance report. During the reporting period, the company achieved an operating income of 9...
2024 CSCO guide major update! Schwarzhe was included in the Level I recommendation, and goliximitinib was recommended for the first time, breaking through the bottleneck of treating difficult tumor targets
SHANGHAI, April 27, 2024/PRNewswire/ -- From April 26 to 27, 2024, the Chinese Society of Clinical Oncology (CSCO) guidelines conference was held in Jinan. In the 2024 CSCO diagnosis and treatment guidelines released at this conference, the two original innovative drugs independently developed by Dizhe Pharmaceutical (stock code: 688192.SH), and golisitinib, were both included in the guidelines as recommended drugs. Schwarzhe was recommended by the “CSCO Guidelines for the Diagnosis and Treatment of Non-small Cell Lung Cancer (2024 Edition)” at Level I, which targets experience in this guideline
Breakthrough in Lung Cancer Treatment: Dizal to Unveil Groundbreaking Results of Sunvozertinib for Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations at 2024 ASCO Annual Meeting
Dizal (SSE:688192), a biopharmaceutical company committed to developing groundbreaking new medicines for the treatment of cancer and immunological...
No Data